Neurocrine Biosciences combines a perfect Piotroski F-Score of 9 out of 9, a wide economic moat, and 42% revenue growth at a PEG of 0.45 and forward P/E of 12.5x — making it one of the higher-conviction quality-growth combinations in the specialty pharmaceutical sector — though heavy revenue concentration in a single product line and current negative price momentum create real near-term risk.
Thesis pillars
- Revenue Growth At Value Peg→Stable
- Wide Moat High Quality Compounder→Stable
- Earnings Beat Track Record↑Improving
- +1 more pillar — see the Why tab for full reasoning
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis
Temporary headwind edge
Healthcare · Drug Manufacturers - Specialty & Generic
Wait — supporting gate not met yet. Price is at or below entry $160.32 but weak momentum; recent C-suite change still blocks BUY_NOW. Key risks: Concentration risk — Product: INGREZZA; Negative momentum.
Neurocrine Biosciences discovers and commercializes treatments for neurological, psychiatric, endocrine, and immunological disorders, with INGREZZA (valbenazine) for tardive dyskinesia and Huntington's disease chorea and CRENESSITY (crinecerfont) for classic congenital adrenal... Read more
Wait — supporting gate not met yet. Price is at or below entry $160.32 but weak momentum; recent C-suite change still blocks BUY_NOW. Key risks: Concentration risk — Product: INGREZZA; Negative momentum. Chart setup: No clear chart pattern; technical signals are mixed. Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 0.45, quality 8.3/10, growth 9.1/10). Score 7.1/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, earnings proximity 73d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: moderate.
About Neurocrine Biosciences, Inc.
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences reported $2.51 billion in INGREZZA (valbenazine) net product sales for 2025 and $301.2 million in CRENESSITY (crinecerfont) net product sales during its first full year post-December 2024 FDA approval, making the San Diego-based biopharmaceutical company two-product commercial. INGREZZA — the first FDA-approved treatment for tardive dyskinesia, approved May 2017, and also approved for Huntington's disease chorea in August 2023 — remains the primary revenue driver.
Neurocrine Biosciences earns revenue through U.S. prescription sales of INGREZZA distributed through a limited specialty network of select specialty pharmacy providers, wholesale distributors, and specialty distributors; CRENESSITY is sold exclusively through a single specialty pharmacy provider, consistent with its rare disease focus. A specialized sales force of approximately 600 professionals targets neurology, psychiatry, long-term care, and rare disease prescribers. Manufacturing is fully outsourced to third-party CMOs and API suppliers, with multiple manufacturers and long-term commercial supply agreements in place to support continued production. Royalties and collaboration revenues from elagolix (for endometriosis and uterine fibroids) flow through the collaboration with AbbVie, which retains global commercialization rights. INGREZZA faces competition from AUSTEDO (deutetrabenazine), marketed by Teva Pharmaceuticals Industries, while CRENESSITY competes primarily with high-dose corticosteroid monotherapy as the existing standard of care for CAH.
Show full overview
INGREZZA's commercial longevity is anchored by 22 FDA Orange Book-listed U.S. patents expiring between 2027 and 2040, with the core active pharmaceutical ingredient patent (U.S. Patent No. 8,039,627) extended to 2031 via patent term extension. Settlement agreements reached in 2023 with all ANDA filers grant generic entrants the right to launch generic valbenazine beginning March 1, 2038, or earlier under certain circumstances — establishing a defined exclusivity window. Pipeline programs osavampator (Phase 3 in MDD, initial topline data expected 2027) and direclidine (Phase 3 in schizophrenia, initial data also expected 2027) are intended to diversify the revenue base ahead of the 2038 generic entry date, though both face binary readout risk.
See also: Healthcare · Drug Manufacturers - Specialty & Generic
From Neurocrine Biosciences, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-08-16Recent Developments — Neurocrine Biosciences, Inc.
Latest news
- NEWS Neurocrine (NBIX) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates - Yahoo Finance — Yahoo Finance neutral
- NEWS AMG National Trust Bank Acquires Shares of 12,326 Neurocrine Biosciences, Inc. $NBIX - MarketBeat — MarketBeat neutral
- NEWS Is Neurocrine (NBIX) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance — Yahoo Finance positive
- NEWS Neurocrine Biosciences Inc (NBIX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey — TradingKey neutral
- NEWS Neurocrine Biosciences (NBIX) Appoints Samir Siddhanti As Chief Business Officer - Yahoo Finance — Yahoo Finance positive
Generated 2026-08-16T18:22:07Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductINGREZZA10-K Item 1: 'INGREZZA net product sales were $2.51 billion for 2025... and accounted for a significant portion of our total net product sales during each of these years'
- MEDIUMCustomerconcentrated customers10-K Item 1A: 'Our customers are concentrated and therefore the loss of a significant customer may harm our business'
- LOWcounterpartysingle specialty pharmacy provider10-K Item 1: 'we sell CRENESSITY in the U.S. through a single specialty pharmacy provider'
Material Events(8-K, last 90d)
- 2026-05-28Item 5.02LOWShareholders approved amendment of 2025 Equity Incentive Plan at May 27, 2026 Annual Meeting. Three Class III directors elected for terms expiring 2029. Ernst & Young LLP ratified as auditor for FY2026. No executive departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait — supporting gate not met yet. Price is at or below entry $160.32 but weak momentum; recent C-suite change still blocks BUY_NOW. Key risks: Concentration risk — Product: INGREZZA; Negative momentum. Chart setup: No clear chart pattern; technical signals are mixed. Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 0.45, quality 8.3/10, growth 9.1/10). Target $190.41 (+24.7%), stop $147.09 (−3.8%), A.R:R 2.9:1. Score 7.1/10, moderate confidence.
Take-profit target: $190.41 (+24.7% upside). Target $190.41 (+24.7%), stop $147.09 (−3.8%), A.R:R 2.9:1. Stop-loss: $147.09.
Concentration risk — Product: INGREZZA; Negative momentum.
Neurocrine Biosciences, Inc. trades at a P/E of 22.3 (forward 12.8). TrendMatrix value score: 7.2/10. Verdict: Buy (Wait for Entry).
36 analysts cover NBIX with a consensus score of 4.3/5. Average price target: $212.
What does Neurocrine Biosciences, Inc. do?Neurocrine Biosciences discovers and commercializes treatments for neurological, psychiatric, endocrine, and...
Neurocrine Biosciences discovers and commercializes treatments for neurological, psychiatric, endocrine, and immunological disorders, with INGREZZA (valbenazine) for tardive dyskinesia and Huntington's disease chorea and CRENESSITY (crinecerfont) for classic congenital adrenal hyperplasia as its two FDA-approved commercial products. INGREZZA generated $2.51 billion in net product sales in 2025; CRENESSITY generated $301.2 million in its first full year following December 2024 FDA approval.